Molecular Screening for Cancer Treatment Optimization (MOSCATO 02)
The primary objective of the study is to use high throughput molecular analysis (CGH Array and sequencing) to treat patients with metastatic cancer with targeted therapeutics in order to improve the progression free survival compared to the previous treatment line.
The secondary objectives are to investigate clinical practical feasibility of such technics, to potentially improve the overall survival of patients and to describe molecular portrait of Phase 1 candidates.
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
|Official Title:||Molecular Screening Analysis Used as Decision Tool for Targeted Molecular Treatment|
- Progression free survival (PFS) using a targeted treatment selected by molecular profiling compared to the PFS for the most recent regimen [ Time Frame: From date of start of targeted treatment oriented by MOSCATO until the date of first progression or date of death from any cause, whichever came first, assessed up to 1 year ] [ Designated as safety issue: No ]Progression according to RECIST criteria or clinical progression or death of any cause
- Number of patient who received a targeted treatment oriented by molecular profiling [ Time Frame: From the start to the end of enrollment, up to 3 years ] [ Designated as safety issue: No ]Number of patient who received a targeted treatment oriented by molecular profiling
- Progression free Survival, Overall Survival and Response Rate [ Time Frame: Until progression, up to 1 year ] [ Designated as safety issue: No ]Comparison of Progression Free Survival, Overall Survival and Response Rate between patients with targeted treatment and others enrolled patients.
|Study Start Date:||October 2011|
|Estimated Study Completion Date:||October 2019|
|Estimated Primary Completion Date:||October 2019 (Final data collection date for primary outcome measure)|
|Experimental: Patients with non curable metastatic cancer||
Procedure: Tumoral biopsy
Every enrolled patient undergoes tumoral biopsy
Please refer to this study by its ClinicalTrials.gov identifier: NCT01566019
|Institut Gustave Roussy||Recruiting|
|Villejuif, Val de Marne, France, 94805|
|Contact: Jean-Charles SORIA, MD, PhD +33 1 42 11 42 96 firstname.lastname@example.org|
|Contact: Christophe MASSARD, MD +33 04 42 11 52 10 email@example.com|
|Principal Investigator: Jean-Charles SORIA, MD, PhD|
|Principal Investigator:||Jean-Charles SORIA, MD, PhD||Gustave Roussy, Cancer Campus, Grand Paris|